Neuphoria Therapeutics (NEUP) Goodwill & Intangibles (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Goodwill & Intangibles of $13.2 million for Q1 2026, down 2.01% year-over-year from $13.4 million in Q1 2025, and little changed quarter-over-quarter from $13.2 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Goodwill & Intangibles (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Goodwill & Intangibles for 7 consecutive years, with $13.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Goodwill & Intangibles fell 2.01% year-over-year to $13.2 million; the TTM figure through Mar 2026 stood at $13.2 million (down 2.01% YoY), while the FY2025 annual figure was $13.4 million, down 5.04% from the prior year.
- Goodwill & Intangibles steadied at $13.2 million in Q1 2026 per NEUP's latest filing, from $13.2 million in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $16.3 million in Q2 2022 and bottomed at $13.2 million in Q1 2026.
- Historically, Goodwill & Intangibles has averaged $14.1 million across 5 years, with a median of $14.2 million in 2024.
- Annual changes were most pronounced in 2022 — Goodwill & Intangibles surged 89.67% — and 2023, when it retreated 8.41%.
- Neuphoria Therapeutics' Goodwill & Intangibles stood at $16.3 million in 2022, then fell by 9.99% to $14.6 million in 2023, then decreased by 7.48% to $13.5 million in 2024, then decreased by 2.45% to $13.2 million in 2025, then dropped by 0.45% to $13.2 million in 2026.
- Business Quant data shows NEUP's Goodwill & Intangibles at $13.2 million in Q1 2026, $13.2 million in Q4 2025, and $13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.15 Mn |
| Dec 31, 2025 | 13.21 Mn |
| Sep 30, 2025 | 13.31 Mn |
| Jun 30, 2025 | 13.44 Mn |
| Mar 31, 2025 | 13.42 Mn |
| Dec 31, 2024 | 13.54 Mn |
| Sep 30, 2024 | 14.21 Mn |
| Jun 30, 2024 | 14.16 Mn |
| Mar 31, 2024 | 14.26 Mn |
| Dec 31, 2023 | 14.64 Mn |
| Sep 30, 2023 | 14.54 Mn |
| Jun 30, 2023 | 14.90 Mn |
| Jun 30, 2022 | 16.26 Mn |
| Jun 30, 2021 | 8.57 Mn |
| Jun 30, 2020 | 7.42 Mn |